|Last Price$0.59||Day Change (%)1.24%|
|Open Price$0.58||Day Change ($)0.01|
|Day Range0.58–0.59||52-Week Range0.29–1.59|
As of Wed 6/29/2016 11:17:00 AM | USD
Global Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Pipeline Review, H1 2016 - Analysis, Technologies & Forecasts - Key Vendors: AbbVie, Bavarian Nordic, GTx - Research and Markets
GTx GTXI announced Thursday that the Data Safety Monitoring Board has given it the green light to proceed with Phase III trials for Acapodene. We're leaving our fair value estimate unchanged as we had anticipated a smooth interim review. In our opinion, Acapodene's potential exposure to generic ...
GTx adds a European partner.
We are raising GTx's fair value on recent positive Phase II trial results for Ostarine.